The European Commission and the German pharmaceutical firm CureVac said on Thursday they were in advanced talks to reach an agreement on the delivery of at least 225 million doses of a potential COVID-19 vaccine to EU member states.
“Today we concluded talks with the European company CureVac to increase the chances of finding an effective coronavirus vaccine,” said EU’s health chief, Stella Kyriakides, adding that the move fulfils EU’s vaccine strategy, meaning “a vaccine for all.”
A contract with CureVac would give EU member states the possibility to purchase the vaccine and to donate it to lower and middle income countries.
“Each round of talks that we conclude with the pharmaceutical industry brings us closer to beating this virus,” said the Commission’s chief, Ursula von der Leyen.
In July the European Investment Bank and CureVac signed a €75 million loan agreement for the development and large-scale production of vaccines, including CureVac’s vaccine candidate against COVID-19.
EU’s Executive arm is also in talks with American pharmaceutical company Johnson & Johnson and the French/multinational firm Sanofi, for their vaccines under development, while it also agreed last week a purchase deal with AstraZeneca, that could provide at least 300 million doses of the shot the company is developing with Oxford University.